Ervogastat is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor. Ervogastat reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH).
靶点:
Transferase
参考文献:
1. PFIZER INVESTOR DAY FEATURES SIGNIFICANT NUMBER OF PIPELINE ADVANCES FOR COVID-19 PROGRAMS AND ACROSS NUMEROUS THERAPEUTIC AREAS